# Trade Mark Journal No.2026/010 6 March 2026

## UK00004340580 13 February 2026 (5)

NAVSYRNA

International priority date claimed: 28 August 2025 (United States of America) (99363013)

Class 5
  Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events.

Amgen Inc.

Representative: Stevens Hewlett & Perkins